We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

63 hedge funds and large institutions have $148M invested in Adamas Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,461% more call options, than puts

Call options by funds: $819K | Put options by funds: $23K

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

5% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 20

6% less funds holding

Funds holding: 67 → 63 (-4)

6% less capital invested

Capital invested by funds: $157M → $148M (-$9.8M)

36% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 11

Holders
63
Holders Change
-4
Holders Change %
-5.97%
% of All Funds
1.1%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
7
Increased
19
Reduced
20
Closed
11
Calls
$819K
Puts
$23K
Net Calls
+$796K
Net Calls Change
+$629K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$5.93M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$1.09M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$859K
4
ACM
Altium Capital Management
New York
+$750K
5
ACM
AIGH Capital Management
Maryland
+$728K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.35M
2
SCM
Silverarc Capital Management
Massachusetts
-$1.22M
3
Two Sigma Investments
Two Sigma Investments
New York
-$1.2M
4
OM
Opaleye Management
Massachusetts
-$1.02M
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$867K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBV
51
United Bank (Virginia)
Virginia
$55K +$54.4K +11,200 New
Capstone Investment Advisors
52
Capstone Investment Advisors
New York
$50K +$49.2K +10,123 New
Osaic Holdings
53
Osaic Holdings
Arizona
$21K -$9.71K -2,000 -32%
Rockefeller Capital Management
54
Rockefeller Capital Management
New York
$17K – – –
UBS Group
55
UBS Group
Switzerland
$11K +$3.33K +685 +43%
CG
56
Cutler Group
California
$5K – – –
TC
57
Truvestments Capital
Florida
$3K – – –
Wells Fargo
58
Wells Fargo
California
$2K -$175 -36 -6%
CWA
59
Clearview Wealth Advisors
Oregon
$1K – – –
Royal Bank of Canada
60
Royal Bank of Canada
Ontario, Canada
$1K – – –
APA
61
American Portfolios Advisors
New York
$737 – – –
BNP Paribas Financial Markets
62
BNP Paribas Financial Markets
France
$5 – – –
GCP
63
GSA Capital Partners
United Kingdom
– -$557K -105,551 Closed
Fisher Asset Management
64
Fisher Asset Management
Washington
– -$316K -59,771 Closed
SFI
65
Susquehanna Fundamental Investments
Pennsylvania
– -$214K -40,590 Closed
LSA
66
Leonteq Securities AG
Switzerland
– -$158K -30,000 Closed
JF
67
Jump Financial
Illinois
– -$122K -23,191 Closed
EGM
68
Engineers Gate Manager
New York
– -$97K -18,434 Closed
Squarepoint
69
Squarepoint
New York
– -$93K -17,561 Closed
XT
70
XTX Topco
Cayman Islands
– -$86K -16,357 Closed
Deutsche Bank
71
Deutsche Bank
Germany
– -$72K -13,620 Closed
DAM
72
Deltec Asset Management
New York
– -$53K -10,000 Closed
TRCT
73
Tower Research Capital (TRC)
New York
– -$40K -7,520 Closed
1 2
3

ADMS Hedge Fund Activity: Q3 2021 in Review

63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2021, worth a combined $148M — down 6.2% from $157M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ADMS and 7 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 19 added.

The largest buyer was Stonepine Capital Management, adding an estimated $5.93M. The largest seller was Point72 Asset Management, cutting an estimated $5.35M.

  • 63 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2021, down from 67 in Q2 2021.
  • Funds reported $148M of Adamas Pharmaceuticals stock for Q3 2021, down 6.2% quarter-over-quarter.
  • 7 funds opened new Adamas Pharmaceuticals positions in Q3 2021 and 11 closed out, a net change of -4 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2021 was Stonepine Capital Management, an estimated $5.93M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2021 was Point72 Asset Management, an estimated $5.35M sold.

Based on aggregated 13F filings for Q3 2021.